Integrated analysis of a NLRP3-dependent adaptive resistance mechanism to pembrolizumab immunotherapy in advanced gastroesophageal cancer
Research Grant
Administered By
Medicine, Medical Oncology
Awarded By
Merck Sharp & Dohme
Start Date
January 21, 2022
End Date
January 21, 2026
Administered By
Medicine, Medical Oncology
Awarded By
Merck Sharp & Dohme
Start Date
January 21, 2022
End Date
January 21, 2026